Xcelom

Xcelom is a Hong Kong-based biotechnology company specializing in non-invasive prenatal testing (NIPT) and molecular diagnostics. The company was founded to commercialize the pioneering research of Professor Dennis Lo from the Chinese University of Hong Kong, who is widely recognized for discovering the presence of fetal DNA in maternal plasma. Xcelom's flagship product, SafeT21Express, utilizes next-generation sequencing (NGS) and advanced bioinformatics to screen for chromosomal abnormalities with high sensitivity and specificity. This technology allows for the detection of conditions like Down syndrome, Edwards syndrome, and Patau syndrome without the miscarriage risks associated with invasive procedures like amniocentesis. Operating out of the Hong Kong Science Park, the company provides a range of genetic testing services including screening for microdeletions and monogenic diseases. Xcelom serves a broad network of private and public hospitals and clinics, maintaining a dominant position in the regional prenatal screening market.